This is particularly relevant in patients with NSCLC, where EGFR mutations and ALK gene fusions are found in approximately 30% and 4%–6% of patients, respectively.17–19 Gefitinib, an EGFR TKI, was granted an accelerated FDA approval in 2003, for treatment of locally advanced or metastatic NSCLC refractory to platinum and docetaxel. This evidence concerns the gene ALK and non-small cell lung carcinoma.